FDA expands use of Xgeva to include giant cell tumor of the bone

The FDA approved the use of Amgen's Xgeva, or denosumab, to treat adults and some adolescents with giant cell tumor of the bone that is unresectable or where surgery is likely to result in severe morbidity. The approval makes denosumab the first and only approved drug for this condition. Xgeva, a fully human monoclonal antibody, was previously approved for treatment of osteoporosis and for prevention of skeletal-related events in adults with bone metasteses and solid tumors.

View Full Article in:

Pharmaceutical Business Review Online · Medscape (free registration) · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID